Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1772932 Target Snapshot

Mitotic checkpoint serine/threonine-protein kinase BUB1 · SINGLE PROTEIN · Homo sapiens

1,563Compounds
86Assays
3Approved Drugs
1,500.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt O43683. Use UniProt O43683 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt O43683 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Mitotic checkpoint serine/threonine-protein kinase BUB1 as ChEMBL target CHEMBL1772932, mapped to UniProt O43683. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Mitotic checkpoint serine/threonine-protein kinase BUB1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1772932
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O43683
Mitotic checkpoint serine/threonine-protein kinase BUB1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Mitotic checkpoint serine/threonine-protein kinase BUB1 is the right protein anchor across sources, using UniProt O43683 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMitotic checkpoint serine/threonine-protein kinase BUB1
UniProt AccessionO43683
Component TypeProtein
Sequence Length1085 aa

Mitotic checkpoint serine/threonine-protein kinase BUB1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Mitotic checkpoint serine/threonine-protein kinase BUB1, mapped to UniProt O43683. Sequence length is 1085 aa.

Mapped IDO43683
Review nameMitotic checkpoint serine/threonine-protein kinase BUB1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase III
2
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC501,273.0
EC501.0
KD226.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5084426 9.0 IC50 1.0 Preclinical
CHEMBL5084426 8.68 Kd 2.1 Preclinical
CHEMBL6062775 8.62 IC50 2.4 Preclinical
CHEMBL5783916 8.59 IC50 2.6 Preclinical
CHEMBL5839408 8.59 IC50 2.58 Preclinical
CHEMBL5855460 8.59 IC50 2.6 Preclinical
CHEMBL5882408 8.52 IC50 3.0 Preclinical
CHEMBL5939177 8.52 IC50 3.0 Preclinical
CHEMBL6023600 8.52 IC50 3.0 Preclinical
CHEMBL5823098 8.48 IC50 3.3 Preclinical
Distribution

pChEMBL Value Distribution

34
5.0
76
5.5
91
6.0
125
6.5
223
7.0
327
7.5
249
8.0
10
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GILTERITINIB
CHEMBL3301622
Approved 2018
ERLOTINIB
CHEMBL553
Approved 2004
Assay Landscape

Assay Landscape

86
Total Assays
1,082
Tested Compounds
2
Assay Types
Binding — 84 assays, 1,082 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 58 550 7.2
assay format 12 0
cell-based format 8 521 7.4
subcellular format 6 11 6.2
Functional — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 1 5.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine